2024-11-0920211687-832910.1186/s41983-021-00353-w2-s2.0-85111282525http://dx.doi.org/10.1186/s41983-021-00353-whttps://hdl.handle.net/20.500.14288/14621Attention-deficit hyperactivity disorder (ADHD) with its high prevalence is a growing area of concern and research, whereas exact underlying pathophysiology remains unknown. Behavioral therapy and multiple medications include methylphenidate, atomoxetine, and amphetamines while trigeminal nerve stimulator (TNS) is the first medical device in ADHD with FDA approval. The aim of this article is to evaluate the latest studies in this field.NeurosciencesLetter678750200002N/A1842